Even as the World Trade Organization (WTO) members continue to remain divided on the waiver of intellectual property (IP) rights for Covid-related vaccine technologies, India, South Africa, and other developing countries have resuscitated their campaign to extend the temporary waiver of IP for Covid vaccines to coronavirus drugs at the WTO.
A temporary patent waiver was granted for five years by members of the WTO in June last year for the manufacture of Covid-19 vaccines. After six months, it was agreed to begin discussions regarding including therapeutics and diagnostics under the scope of this waiver, as proposed by India and South Africa.
India's Commerce and Industry Minister Piyush Goyal said the IP rights waiver for five years agreed upon during the 12th ministerial conference of the WTO would help developing countries manufacture patented Covid-19 vaccines.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze